Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 0.33 |
| ▸ | KDM5A | P29375 | 6/20 | 0.33 |
| ▸ | PHF8 | Q9UPP1 | 2/20 | 0.33 |
| ▸ | KDM4A | O75164 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | BCHE | P06276 | 3/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | KDM5C | P41229 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22021659 | 0.83 | EPHX2 (0.39) | EPHX2CNR1ALDH1A1KDM4CKDM5A | |
| SCHEMBL22166526 | 0.82 | EPHX2 (0.40) | EPHX2CNR1ALDH1A1KDM4CKDM5A | |
| SCHEMBL23639761 | 0.81 | EPHX2 (0.48) | EPHX2CNR1ALDH1A1KDM4CKDM5A | |
| SCHEMBL20216159 | 0.77 | ALDH1A1 (0.40) | EPHX2CNR1ALDH1A1 | |
| SCHEMBL18743131 | 0.77 | ALDH1A1 (0.35) | EPHX2CNR1ALDH1A1 | |
| SCHEMBL21166472 | 0.76 | ALDH1A1 (0.41) | EPHX2CNR1ALDH1A1 | |
| SCHEMBL19176543 | 0.76 | ALDH1A1 (0.41) | EPHX2CNR1ALDH1A1 | |
| SCHEMBL12847912 | 0.75 | EPHX2 (0.50) | EPHX2CNR1ALDH1A1KDM4CKDM5A | |
| SCHEMBL23639935 | 0.75 | EPHX2 (0.34) | EPHX2ACHEBCHE | |
| SCHEMBL22166535 | 0.75 | EPHX2 (0.53) | EPHX2CNR1ALDH1A1KDM4CKDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | Accutar Biotechnology (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11642342-B2 | Combinations of estrogen receptor degraders and cyclin-dependent kinase inhibitors for treating cancer | CDK3, CDK4, CDK1 | EPHX2 1763/4885CNR1 844/4885ALDH1A1 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.